---
title: "UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292125695.md"
description: "Kirby McInerney LLP is investigating potential securities law violations by Unicycive Therapeutics (NASDAQ: UNCY) and its management. The probe follows a June 30, 2026 announcement that the FDA issued a second Complete Response Letter for oxylanthanum carbonate due to manufacturing deficiencies, causing shares to drop ~39%. No lawsuit has been filed yet; the firm seeks investors with information regarding their rights."
datetime: "2026-07-09T00:11:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292125695.md)
  - [en](https://longbridge.com/en/news/292125695.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292125695.md)
generator: "portal-rs"
---

# UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

**UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.**

The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

\[LEARN MORE ABOUT THE INVESTIGATION\]

**What Happened?**

On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) regarding the Company’s resubmitted New Drug Application for oxylanthanum carbonate for kidney disease therapy. The Company disclosed that the CRL was based on the same third-party manufacturing deficiencies identified in the prior June 2025 CRL. On this news, the price of Unicycive shares declined by $3.01 per share, or approximately 39%, from $7.70 per share on June 29, 2026 to close at $4.69 on June 30, 2026.

**What Should I Do?**

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Unicycive securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

\[LEARN MORE ABOUT SECURITIES CLASS ACTIONS\]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP  
Lauren Molinaro, Esq.  
212-699-1171  
https://www.kmllp.com  
https://securitiesleadplaintiff.com/  
investigations@kmllp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260708004803/en/

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY](https://longbridge.com/en/news/298209708.md)
- [UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP](https://longbridge.com/en/news/298082283.md)
- [Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action](https://longbridge.com/en/news/297971037.md)
- [Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | UNCY Stock News](https://longbridge.com/en/news/297642457.md)
- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**